HRS-4642 — Investigational Agent
KRAS Inhibitor · Phase 1/2 · Jiangsu Hengrui Pharmaceuticals
Mechanism of Action
Selective small-molecule inhibitor of the KRAS G12D mutant protein that binds and stabilizes an inactive conformation, blocking nucleotide exchange and effector engagement to suppress RAS-MAPK/PI3K signaling in G12D-driven tumors.
Investigational Indications
- KRAS G12D-mutant NSCLC
- KRAS G12D-mutant pancreatic cancer
- KRAS G12D-mutant biliary tract cancer
- Other KRAS G12D solid tumors